US20240018178A1 - Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same - Google Patents
Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same Download PDFInfo
- Publication number
- US20240018178A1 US20240018178A1 US18/370,241 US202318370241A US2024018178A1 US 20240018178 A1 US20240018178 A1 US 20240018178A1 US 202318370241 A US202318370241 A US 202318370241A US 2024018178 A1 US2024018178 A1 US 2024018178A1
- Authority
- US
- United States
- Prior art keywords
- benzimidazole
- carbohydrate
- glucose
- conjugate compound
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003443 antiviral agent Substances 0.000 title abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 7
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title description 6
- 239000000126 substance Substances 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims description 89
- 239000008103 glucose Substances 0.000 claims description 48
- -1 2-aminobenzimidazole compound Chemical class 0.000 claims description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 27
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 150000001720 carbohydrates Chemical class 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 235000014633 carbohydrates Nutrition 0.000 claims description 18
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 9
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 6
- 229930182830 galactose Natural products 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 claims description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 3
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N 3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 claims description 3
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 claims description 3
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 claims description 3
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 3
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 claims description 3
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 claims description 3
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 claims description 3
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 claims description 3
- 206010056474 Erythrosis Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- 150000001320 aldopentoses Chemical class 0.000 claims description 3
- 150000001330 aldotetroses Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 3
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- 125000001769 aryl amino group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000004986 diarylamino group Chemical group 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 150000002337 glycosamines Chemical class 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 150000002338 glycosides Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 150000002466 imines Chemical class 0.000 claims description 3
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims description 3
- 150000002581 ketopentoses Chemical class 0.000 claims description 3
- 150000002586 ketotetroses Chemical class 0.000 claims description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000006413 ring segment Chemical group 0.000 claims description 3
- 150000003573 thiols Chemical group 0.000 claims description 3
- 125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 111
- 206010028980 Neoplasm Diseases 0.000 description 30
- 201000011510 cancer Diseases 0.000 description 28
- 239000003814 drug Substances 0.000 description 28
- 241000700605 Viruses Species 0.000 description 23
- 230000012010 growth Effects 0.000 description 20
- 229940079593 drug Drugs 0.000 description 16
- 230000000840 anti-viral effect Effects 0.000 description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 150000001556 benzimidazoles Chemical class 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 12
- 102000029749 Microtubule Human genes 0.000 description 10
- 108091022875 Microtubule Proteins 0.000 description 10
- 210000004688 microtubule Anatomy 0.000 description 10
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 231100000820 toxicity test Toxicity 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 230000009036 growth inhibition Effects 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 4
- RKMOQLOKJZARIG-UHFFFAOYSA-N 6-propylsulfanyl-1h-benzimidazol-2-amine Chemical compound CCCSC1=CC=C2N=C(N)NC2=C1 RKMOQLOKJZARIG-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 description 4
- 229960005473 fenbendazole Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229960004500 flubendazole Drugs 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229960003439 mebendazole Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical class C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 3
- DMWJTTJFNBREOO-SSPAHAAFSA-N N1=CNC2=C1C=CC=C2.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound N1=CNC2=C1C=CC=C2.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO DMWJTTJFNBREOO-SSPAHAAFSA-N 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 229960002669 albendazole Drugs 0.000 description 3
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000008196 pharmacological composition Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003214 pyranose derivatives Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- WINHLTQNRABBSW-UHFFFAOYSA-N (2-amino-3h-benzimidazol-5-yl)-(4-fluorophenyl)methanone Chemical compound C=1C=C2NC(N)=NC2=CC=1C(=O)C1=CC=C(F)C=C1 WINHLTQNRABBSW-UHFFFAOYSA-N 0.000 description 2
- LOMHJEGAUNMOOE-VANKVMQKSA-N (2r,3s,4s,5r)-2-amino-2,3,4,5,6-pentahydroxyhexanal Chemical group O=C[C@@](O)(N)[C@@H](O)[C@@H](O)[C@H](O)CO LOMHJEGAUNMOOE-VANKVMQKSA-N 0.000 description 2
- LOMHJEGAUNMOOE-ARQDHWQXSA-N (2s,3s,4r,5r)-2-amino-2,3,4,5,6-pentahydroxyhexanal Chemical group O=C[C@](O)(N)[C@@H](O)[C@H](O)[C@H](O)CO LOMHJEGAUNMOOE-ARQDHWQXSA-N 0.000 description 2
- GPMHHSJZGVOEFS-UHFFFAOYSA-N 2-Amino-5-benzoylbenzimidazole Chemical compound C1=C2NC(N)=NC2=CC=C1C(=O)C1=CC=CC=C1 GPMHHSJZGVOEFS-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124339 anthelmintic agent Drugs 0.000 description 2
- 239000000921 anthelmintic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940072240 direct acting antivirals Drugs 0.000 description 2
- 229940125371 direct-acting antiviral drugs Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002454 idoses Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 235000020061 kirsch Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BHFLSZOGGDDWQM-UHFFFAOYSA-N 1h-benzimidazole;carbamic acid Chemical compound NC(O)=O.C1=CC=C2NC=NC2=C1 BHFLSZOGGDDWQM-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- UGWQMIXVUBLMAH-IVVFTGHFSA-N [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 UGWQMIXVUBLMAH-IVVFTGHFSA-N 0.000 description 1
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940014461 combivir Drugs 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960001418 dasabuvir Drugs 0.000 description 1
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940029169 harvoni Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940115474 intelence Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 229940076563 sovaldi Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940108442 valtrex Drugs 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Definitions
- the present invention relates to a novel benzimidazole derivative, a preparation method thereof, and use thereof as an anticancer or anti-virus agent.
- Benzimidazole is a compound in which an imidazole ring is attached to a benzene ring, and has various bioactivities and physiological actions, so it is attracting attention as a mother nucleus of various drugs. It has been reported that compounds having such a benzimidazole structure exhibit effects against various diseases depending on substituent groups. For example, it has been developed as an anti-inflammatory analgesic agent, antifungal agent, anticancer agent, anthelmitic agent, antihistamine agent, and the like.
- Benzimidazole has been published in many papers as having the property of entering cells through a cell wall and inhibiting the formation of microtubules (see: Chem Biol Drug Des., 2017 July; 90(1):40-51; Scientific REPORTS, 2018, 8:11926; and ANTICANCER RESEARCH, 29: 3791-3796, 2009).
- benzimidazole invades normal cells and abnormal cells (that is, cancer-expressing cells and virus-infected cells) without distinguishing them, thereby equally inhibiting the formation of microtubules in normal cells and abnormal cells.
- cancer cells and virus-infected cells show the property of absorbing large amounts of glucose, but microtubules are indispensably used to move GLUT channels to the cell wall, and cancer cells have been reported to produce about 1000 times more GLUT channels than normal cells (see: L. Quan et al. I Journal of Molecular Structure 1203 (2020) 127361).
- benzimidazole derivatives when intensively injected into cancer cells or virus-infected cells rather than normal cells to inhibit the formation of microtubules, the production of GLUT channels may be inhibit and the absorption of glucose can be blocked, and as a result, the growth of cancer cells or the growth of viruses in virus-infected cells can be significantly inhibited, whereby the body's immune system is known to attack cancer cells or virus-infected cells whose growth is inhibited as described above, thereby exhibiting an anticancer effect or an antiviral effect (see: EXPERIMENTAL AND THERAPEUTIC MEDICINE 13: 595-603, 2017).
- benzimidazole derivatives since benzimidazole derivatives usually have low aqueous solubility and low bioabsorbability, they must be administered in high concentrations or in considerable amounts in order to efficiently inhibit the growth of cancer cells or virus growth in virus-infected cells. For this reason, it has been reported that it exhibits considerable side effects even in normal cells (see: Vojnosanit Pregl. 2008 July; 65(7):539-44, Infect Chemother 2018; 50(1):1-10).
- benzimidazole derivatives can be administered together with drugs that can improve absorption in the gastrointestinal tract (e.g., H2 receptor antagonists such as cimetidine or gastric acid secretion inhibitors), or it has been proposed to introduce a water-soluble substituent to improve the water solubility of the benzimidazole derivative itself.
- drugs that can improve absorption in the gastrointestinal tract e.g., H2 receptor antagonists such as cimetidine or gastric acid secretion inhibitors
- Patent Document 1 International Patent Publication WO1998/051304, published on Nov. 19, 1998) discloses that a 2-carbamate benzimidazole derivative can inhibit the growth of mammalian tumors and cancers and treat viral infections, and it can treat viral infections, but the aqueous solubility and bioabsorption rate are low as described above, and the pharmacological effect is not sufficient.
- Patent Document 2 International Patent Publication WO2005/058870, published on Jun. 30, 2005 discloses that a compound in which a substituent capable of increasing water solubility, such as a 3-hydroxypropyl group, a 2,3-dihydroxypropyl group or a 2-carboxyamide ethyl group is attached to an 2-amino group of the 1-aryl-2-aminobenzimidazole derivative is used as an inhibitor of replication of respiratory syncytial virus, but the aqueous solubility and bioabsorption rate are not sufficient.
- a substituent capable of increasing water solubility such as a 3-hydroxypropyl group, a 2,3-dihydroxypropyl group or a 2-carboxyamide ethyl group is attached to an 2-amino group of the 1-aryl-2-aminobenzimidazole derivative is used as an inhibitor of replication of respiratory syncytial virus, but the aqueous solubility and bioabsorption rate are not sufficient.
- Patent Document 3 International Patent Publication WO1998/056761, published on Dec. 17, 1998) discloses a compound in which a pyranose ring derived from p-D-ribopyranose is substituted with a nitrogen atom at the 1-position of a benzimidazole derivative, and the use thereof in the treatment and prevention of viral infections.
- the pyranose ring can contain 2 to 3 or more hydroxyl groups, the water solubility of the benzimidazole derivative is significantly increased, and the possibility of using it as an injection is also disclosed.
- 2-aminobenzimidazole derivatives such as albendazole, fenbendazole, mebendazole, flubendazole, etc.
- anthelmintic agents are known to exhibit surprising anticancer effects, and are receiving new interest.
- interest is also being given to ways to improve their low water solubility and bioavailability.
- Albendazole and fenbendazole which are used as anthelmintic agents, are benzimidazole carbamate-based compounds, and are absorbed through the cell wall when absorbed into cells, so that they are absorbed equally by virus-infected cells and normal cells. Therefore, it is difficult to selectively absorb these compounds only in cancer cells or virus-infected cells.
- cancer cells and virus-infected cells absorb virus-infected cells absorb a relatively large amount of glucose-containing sugar compounds compared to normal cells or non-virus-infected cells.
- An object of the present invention is to design a new benzimidazole derivative capable of solving the above-described problems, and to provide a simple and economical preparation method thereof and use thereof as an anticancer or antiviral agent.
- the present invention provides a novel benzimidazole-carbohydrate conjugate compound represented by the following Chemical Formula 1:
- the benzimidazole-carbohydrate conjugate compound may be a compound represented by the following Chemical Formula 2:
- the —NH—R 1 moiety may have one of the following structures:
- the benzimidazole moiety in the Chemical Formula 1 or 2, can have any one of the following structures:
- the benzimidazole-carbohydrate conjugate compound may be selected from the following compounds:
- Fenbendazole-D-carbohydrate conjugate compound
- the present invention provides a method for preparing a benzimidazole-carbohydrate conjugate compound represented by the following Chemical Formula 1, characterized in that a carbohydrate is reacted with a 2-aminobenzimidazole compound represented by the following Chemical Formula 1a.
- the benzimidazole-carbohydrate conjugate compound can be prepared by reacting an aldehyde group or a ketone group of a carbohydrate with the 2-amino group of the 2-aminobenzimidazole compound of Chemical Formula 1a to form an imine bond, and cyclizing the carbohydrate moiety:
- the present invention provides a pharmaceutical composition containing the benzimidazole-carbohydrate conjugate compound of Chemical Formula 1.
- the benzimidazole-carbohydrate conjugate compound of Chemical Formula 1 may inhibit the formation of microtubule and inhibit the absorption of sugar compounds including carbohydrates, preferably glucose.
- the benzimidazole-carbohydrate conjugate compound of Chemical Formula 1 may exhibit anticancer or antiviral activity.
- a novel benzimidazole-carbohydrate conjugate compound having anticancer or antiviral activity and a method for producing the same are provided.
- FIG. 1 is a schematic diagram conceptually showing that absorption of glucose is reduced and the growth of virus is inhibited in the GLUT channel.
- FIG. 2 is a diagram showing a growth inhibitory effect of a cancer cell line, which is a result of a toxicity test (24 hours) on a lung cancer cell line.
- FIG. 3 is a diagram showing a growth inhibitory effect of a cancer cell line, which is a result of a toxicity test (72 hours) on a lung cancer cell line.
- FIG. 4 is a diagram showing cell viability in a normal cell line, which is the result of a toxicity test (72 hours) in a normal cell line.
- FIG. 5 is a 1H-NMR spectrum of the albendazole-glucose conjugate compound prepared in Example 1-A.
- FIG. 6 is a 1H-NMR spectrum of the fenbendazole-glucose conjugate compound prepared in Example 1-B.
- FIG. 7 is a 1H-NMR spectrum of the flubendazole-glucose conjugate compound prepared in Example 2-A.
- FIG. 8 is a 1H-NMR spectrum of the mebendazole-glucose conjugate compound prepared in Example 2-B.
- an element when it is described that an element includes another element, it may mean that the first element may further includes any other element without excluding the other element unless a particularly contradictory description is made.
- anticancer agent is a substance that inhibits the growth or proliferation of cancer cells, or such drug.
- antiviral refers to inhibiting the growth of cells infected with a virus
- antiviral agent means a substance that inhibits the growth of cells infected with a virus, or such drug.
- carbohydrate is used as a generic term for organic compounds composed of sugars.
- inhibittion of sugar compound absorption means to inhibit the absorption or entry of sugar compounds into cells.
- tubulin refers to proteins that make up microtubules present in almost all cells of an organism.
- microtubule is a tube which consists of a polymer of proteins called tubulin, which constitutes a cytoskeleton and to which intracellular substances move.
- cell division refers to a phenomenon in which a parent cell of an organism is divided into two cells through nuclear fission and cytoplasmic division.
- the first object of the present invention is to provide a benzimidazole-carbohydrate conjugate compound represented by the following Chemical Formula 1:
- the compound of the Chemical Formula 1 may be understood as a form in which a carbohydrate residue is bound to a 2-amino group of the 2-aminobenzimidazole structure or a form in which an aminated carbohydrate is bound to the 2-position of the benzimidazole structure.
- the benzimidazole-carbohydrate conjugate compound can be a compound represented by the following Chemical Formula 2.
- the —NH—R 1 moiety may have one of the following structures:
- the benzimidazole moiety in the Chemical Formula 1 or 2, can have any one of the following structures:
- the benzimidazole-carbohydrate conjugate compound may be selected from the following compounds:
- Fenbendazole-D-carbohydrate conjugate compound
- the carbohydrate moiety has both a chain structure and a cyclic structure, and the chain structure is thermodynamically more stable in the pentose and hexose, but the chain structure and the cyclic structure are in equilibrium in the solution, Thus, even if only one of the two has a medicinal effect, it does not have a significant effect on the overall pharmacological effect.
- the present invention provides a method for preparing a benzimidazole-carbohydrate conjugate compound represented by the following Chemical Formula 1, characterized in that a carbohydrate is reacted with a 2-aminobenzimidazole compound of the following Chemical Formula 1a to form an imine bond.
- the benzimidazole carbohydrate conjugate compound represented by Chemical Formula 1 can be prepared by reacting an aldehyde group or a ketone group of a carbohydrate with ae 2-amino group of the 2-aminobenzimidazole compound of Formula 1a to form an imine bond, and cyclizing the carbohydrate moiety.
- R 1 , R 2 , R 3 and X are the same as defined above.
- a substituent capable of performing an imine reaction may be previously protected or blocked.
- the benzimidazole-carbohydrate conjugate compound according to the present invention can be prepared by various methods, and an example of the preparation method is provided below.
- Reaction Scheme 1 shows a reaction in which a D-glucose unit is bound to the 2-amino group of 6-alkylthio-2-aminobenzimidazole, which is a precursor of albendazole or fenbendazole.
- an 2-amino group of aminobenzimidazole can be reacted with an aldehyde group of D-glucose (open chain form) to form an imine bond, and thereby, a benzimidazole-carbohydrate conjugate compound, that is, benzimidazole-D-glucose (open chain form) conjugate compound is prepared.
- the benzimidazole-D-glucose (open chain form) conjugate compound may be converted into thermodynamically stable cyclic benzimidazole-D-glucose (cyclic form).
- Reaction Scheme 2 shows the reaction of binding the D-glucose unit to the 2-amino group of 6-alkylcarbonyl-2-aminobenzimidazole, which is a precursor of flubendazole or mebendazole.
- the benzimidazole-carbohydrate conjugate compound obtained as a result of Reaction Schemes 1 and 2 can be isolated and/or purified by a conventional method, and then confirmed by a spectroscopic method (eg, 1H-NMR).
- a third object of the present invention is to provide a pharmaceutical composition or a pharmacological composition containing the benzimidazole-carbohydrate conjugate compound of Chemical Formula 1.
- the benzimidazole-carbohydrate conjugate compound of Chemical Formula 1 can exhibit a pharmacological effect of inhibiting the formation of microtubule and the absorption of carbohydrates, preferably sugar compounds including glucose, and thereby, a pharmacological composition useful for the treatment of disorders that can take advantage of intake or metabolic disorders of carbohydrates, including glucose, can be provided.
- the benzimidazole-carbohydrate conjugate compound of Formula 1 exhibits anticancer or antiviral activity, so that a pharmaceutical composition having anticancer or antiviral activity may be provided.
- fenbendazole-glucose compound which is one of the benzimidazole-carbohydrate conjugate compounds
- FB-G fenbendazole-glucose compound
- the GLUT channel is more activated in cancer cells or virus-infected cells than in normal cells. In particular, it has been reported that cancer cells form 1000 times more GLUT channels than normal cells.
- the benzimidazole-carbohydrate conjugate compound according to the present invention is expected to be more intensively absorbed in cancer cells and virus-infected cells in which GLUT channels are activated than in normal cells (see: L. Quan et al. I Journal of Molecular Structure 1203 (2020) 127361).
- a pharmacological composition in which the benzimidazole-carbohydrate conjugate compound of Chemical Formula 1 is absorbed through a GLUT channel rather than a cell wall.
- a virus is a small particle (average 0.1 um or less) that are smaller a bacteria and cannot be filtered through a bacterial filter (0.22 um), and contains only nucleic acids (DNA or RNA) and a small number of proteins as substances necessary for survival, so it is an organism that lives depending on the host, and if it is infected in the human body, it causes viral diseases.
- Viruses differ in most properties from bacteria, and common antibiotics do not inhibit the growth of virus.
- drugs that weaken or eliminate the action of viruses that have invaded the body are called antiviral therapeutic agents. Because viral infections are difficult to treat with conventional antibiotics, they have no choice but to treat them with antiviral therapeutic agent.
- Antiviral preparations currently being developed and used are drugs that inhibit the growth process of the virus, that is, inhibit the growth rate of the intracellular virus infected with virus, extremely inhibit the number of cells infected with the virus from being increased, so that the body's immune system attacks virus-infected cells and inhibites the virus's growth process below levels that can be removed.
- Antiviral drugs that inhibit the growth of virus are drugs that inhibit the growth of a virus is a drug that inhibites and treats the growth of a virus by interfering with a specific step in the process of the growth of the virus in the cell.
- Antiviral agents are classified into influenza therapeutic agents, herpes therapeutic agents, hepatitis B therapeutic agents, hepatitis C therapeutic agents, AIDS therapeutic agents, etc., depending on the disease group to be treated, and may be used for various diseases depending on the characteristics of the drug.
- Typical antiviral drugs used as influenza therapeutic agents include Tamiflu®, Relenzarotadisk® and Peramivir®, which are used for the treatment of influenza A and influenza B virus infections.
- herpes therapeutic agent typical antiviral agents used for the treatment of herpes simplex virus (HSV) and varicella zoster virus (VZV) infection are Zovirax®, Valtrex®, Famciclovir®, Ocufridine®, and the like.
- a therapeutic agent for hepatitis C is a drug that inhibits the growth of hepatitis C virus and delays the progression of the diseases.
- the combination therapy of interferon injection and ribavirin, which enhances the immune system, has been used for a long time, but relatively recently, direct acting antivirals (DAA) have been developed, and can be treated with just edible drugs, and typical examples are Viramid®, Exviera®, Sovaldi®, Daclatarvir®, and Harvoni®, and the like.
- a drug that inhibites the growth of human immunodeficiency virus (HIV) and delays the progression of the disease is to prevent the expression of resistance by using cocktail therapy in which three or more drugs are taken at the same time, and typical examples are Combivir®, Kivexa®, Trubada®, and Intelence®, and the like.
- antiviral agents there are drugs that inhibit the growth of viruses by enhancing or regulating human immune responses, which are substances produced and secreted by immune cells during infection, and have antiviral effect and immunomodulatory ability.
- Typical examples are Loferon-A®, Intron-A®, Pegasys®, and Aldara® are typical (see: Korea Pharmaceutical Information Center).
- the novel benzimidazole-carbohydrate conjugate compound according to the present invention is mainly absorbed only in cancer cells and virus-infected cells than in normal cells, and then binds to tubulin that forms microtubules, which is a known characteristic of conventional benzimidazole compound derivatives, and interferes with the formation of microtubule, inhibits cell division, whereby it is possible to effectively induce the death of cancer cells and virus-infected cells by blocking the absorption of carbohydrates containing glucose, which is a cellular energy source.
- novel benzimidazole-carbohydrate conjugate compound according to the present invention is absorbed intensively by cancer cells and virus-infected cells, not only it is designed to minimize toxicity to normal cells, but also it is expected to be usefully used as an anticancer and antiviral compound for the treatment of cancer and virus-infections.
- An albendazole-glucose conjugate compound was prepared according to the above reaction scheme, and the reaction procedure and conditions were referred to the methods described in documents (Gokhale, Kearney, and Kirsch, AAPS PharmSciTech, Vol. 10, No. 2, June 2009).
- 1.2 mM aminoalbendazole (CAS #80983-36-4) commercially available: Albendazole amine
- 0.5 M glucose were added to a hydrochloric acid solution (pH 3.45) to prepare a reaction mixture, and reacted at 40 ⁇ 1° C. in a Teflon-coated rubber-stopped glass vial, and diluted with acetate buffer (0.5 M, pH 5.8) to terminate the reaction.
- the solvent was removed, and purified by column chromatography using dichloromethane and 10% methanol to obtain an albendazole-glucose conjugate compound in a yield of 62%.
- the product was analyzed by 1H-NMR spectrum to confirm the formation of an albendazole-glucose conjugate compound (see FIG. 5 ).
- the product was analyzed by 1H-NMR spectrum to confirm generation of a fenbendazole-glucose conjugate compound (see FIG. 6 ).
- a flubendazole-glucose conjugate compound was prepared according to the reaction scheme, and the reaction procedure and conditions were referred to the methods described in documents (Gokhale, Kearney, and Kirsch, AAPS PharmSciTech, Vol. 10, No. 2, June 2009).
- 1.2 mM aminoflubendazole (CAS #82050-13-3) (commercial name: 2-Aminoflubendazole) and 0.5 M glucose were added to a hydrochloric acid solution (pH 3.45) to prepare a reaction mixture, reacted at 40 ⁇ 1° C. in a Teflon-coated rubber-stopped glass vial, and diluted with acetate buffer (0.5 M, pH 5.8) to terminate the reaction.
- the product was analyzed by 1H-NMR spectrum to confirm the formation of a flubendazole-glucose conjugate compound (see FIG. 7 ).
- the product was analyzed by 1H-NMR spectrum to confirm the formation of a mebendazole-glucose conjugate compound (see FIG. 8 ).
- Human lung cancer cell line A549, cervical cancer cell line Hela, and colorectal cancer cell line HT-29 were furnished from Korea Cell Line Bank (KCLB, Seoul, Korea) and cultured in culture medium.
- a humidified cell culture incubator containing 5% CO 2 at 37° C. using DMEM 10% culture flask, fetal bovine serum (FBS), 0.1 mM MEM non-essential amino acids (NEAA), 2 mM L-glutamine, and 1% penicillin-streptomycin were treated with trypsin every 2-3 days according to the guidelines provided by KCLB, and the cells were sub-cultured.
- the culture was cultured until it reached 80-90% confluence, and the cells were continuously transferred to a culture flask for a cancer cell line growth inhibition experiment.
- Cancer cell lines to be tested (human lung cancer cell line A549, cervical cancer cell line Hela, and colorectal cancer cell line HT-29) were seeded in about 10000 cells per well in a 96-well plate. After 24 hours, the three compounds shown in Table 1 below were added to each well at 7 concentrations, and incubated for 72 hours.
- the analysis utilized the principle that the dehydrogenase in living cells decomposes tetrazolium salts to produce formazan, through which living cells were quantitatively evaluated.
- the reduced formazan salt is soluble in the cell culture medium and the amount of formazan is directly proportional to the number of viable cells (see: Slater, T. et al. (1963) Biochem. Biophys. Acta 77:383; van de Loosdrecht, A A, et al. J. Immunol. Methods 174: 311-320, 1994. Alley, M C, et al.; and Cancer Res. 48: 589-601, 1988.)
- FIGS. 2 and 3 The results of the cancer cell line growth inhibition test performed in this test example are shown in FIGS. 2 and 3 .
- FIG. 2 is the results of a toxicity test (24 hr) in a lung cancer cell line
- FIG. 3 is the results of a toxicity test (72 hr) in a lung cancer cell line.
- the normal lung cell line MRC-5 and the normal colon CCD-18Co cell line were furnished from Korea Cell Line Bank (KCLB, Seoul, Korea) and cultured in culture medium.
- a humidified cell culture incubator containing 5% CO 2 at 37° C. using DMEM 10% culture flask, fetal bovine serum (FBS), 0.1 mM MEM non-essential amino acids (NEAA), 2 mM L-glutamine, and 1% penicillin-streptomycin were treated with trypsin every 2-3 days according to the guidelines provided by KCLB, and the cells were sub-cultured.
- the culture was cultured until it reached 80-90% confluence, and the cells were continuously transferred to a culture flask for a cancer cell line growth inhibition experiment.
- Normal cell lines (MRC-5 and CCD-18Co) were seeded in about 10000 cells per well in a 96-well plate. After 24 hours, the three compounds shown in Table 1 below were added to each well at 7 concentrations, and incubated for 72 hours.
- the cell viability and analysis in the normal cell line were performed in the same manner as in Test Example 1, and the results of the toxicity test (72 hours) in the normal cell line are shown in FIG. 4 .
- Table 3 shows that the test results of aminofenbendazole and fenbendazole-glucose conjugate compound were evaluated in comparison with doxorubicin.
- the present invention is available in the pharmaceutical, medical and health industries.
Abstract
Description
- This application is a divisional application of U.S. patent application Ser. No. 17/051,154, filed on Dec. 2, 2020, which is a National Phase patent application of International Patent Application Number PCT/KR2020/013371, filed on Sep. 29, 2020, which claims priority of Korean Patent Application No. 10-2020-0076802, filed Jun. 23, 2020, the entire contents of each of which are incorporated herein by reference.
- The present invention relates to a novel benzimidazole derivative, a preparation method thereof, and use thereof as an anticancer or anti-virus agent.
- Benzimidazole is a compound in which an imidazole ring is attached to a benzene ring, and has various bioactivities and physiological actions, so it is attracting attention as a mother nucleus of various drugs. It has been reported that compounds having such a benzimidazole structure exhibit effects against various diseases depending on substituent groups. For example, it has been developed as an anti-inflammatory analgesic agent, antifungal agent, anticancer agent, anthelmitic agent, antihistamine agent, and the like.
- Benzimidazole has been published in many papers as having the property of entering cells through a cell wall and inhibiting the formation of microtubules (see: Chem Biol Drug Des., 2017 July; 90(1):40-51; Scientific REPORTS, 2018, 8:11926; and ANTICANCER RESEARCH, 29: 3791-3796, 2009). However, it is known that benzimidazole invades normal cells and abnormal cells (that is, cancer-expressing cells and virus-infected cells) without distinguishing them, thereby equally inhibiting the formation of microtubules in normal cells and abnormal cells.
- Further, cancer cells and virus-infected cells show the property of absorbing large amounts of glucose, but microtubules are indispensably used to move GLUT channels to the cell wall, and cancer cells have been reported to produce about 1000 times more GLUT channels than normal cells (see: L. Quan et al. I Journal of Molecular Structure 1203 (2020) 127361).
- Therefore, when benzimidazole derivatives are intensively injected into cancer cells or virus-infected cells rather than normal cells to inhibit the formation of microtubules, the production of GLUT channels may be inhibit and the absorption of glucose can be blocked, and as a result, the growth of cancer cells or the growth of viruses in virus-infected cells can be significantly inhibited, whereby the body's immune system is known to attack cancer cells or virus-infected cells whose growth is inhibited as described above, thereby exhibiting an anticancer effect or an antiviral effect (see: EXPERIMENTAL AND THERAPEUTIC MEDICINE 13: 595-603, 2017).
- However, since benzimidazole derivatives usually have low aqueous solubility and low bioabsorbability, they must be administered in high concentrations or in considerable amounts in order to efficiently inhibit the growth of cancer cells or virus growth in virus-infected cells. For this reason, it has been reported that it exhibits considerable side effects even in normal cells (see: Vojnosanit Pregl. 2008 July; 65(7):539-44, Infect Chemother 2018; 50(1):1-10).
- Therefore, benzimidazole derivatives can be administered together with drugs that can improve absorption in the gastrointestinal tract (e.g., H2 receptor antagonists such as cimetidine or gastric acid secretion inhibitors), or it has been proposed to introduce a water-soluble substituent to improve the water solubility of the benzimidazole derivative itself.
- For example, in Patent Document 1 (International Patent Publication WO1998/051304, published on Nov. 19, 1998) discloses that a 2-carbamate benzimidazole derivative can inhibit the growth of mammalian tumors and cancers and treat viral infections, and it can treat viral infections, but the aqueous solubility and bioabsorption rate are low as described above, and the pharmacological effect is not sufficient.
- Patent Document 2 (International Patent Publication WO2005/058870, published on Jun. 30, 2005) discloses that a compound in which a substituent capable of increasing water solubility, such as a 3-hydroxypropyl group, a 2,3-dihydroxypropyl group or a 2-carboxyamide ethyl group is attached to an 2-amino group of the 1-aryl-2-aminobenzimidazole derivative is used as an inhibitor of replication of respiratory syncytial virus, but the aqueous solubility and bioabsorption rate are not sufficient.
- Patent Document 3 (International Patent Publication WO1998/056761, published on Dec. 17, 1998) discloses a compound in which a pyranose ring derived from p-D-ribopyranose is substituted with a nitrogen atom at the 1-position of a benzimidazole derivative, and the use thereof in the treatment and prevention of viral infections. In the patent document, since the pyranose ring can contain 2 to 3 or more hydroxyl groups, the water solubility of the benzimidazole derivative is significantly increased, and the possibility of using it as an injection is also disclosed. However, only the derivative in which the pyranose ring is linked to the 1-position of benzimidazole is disclosed, and it can be seen that even when benzimidazole contains a 2-amino group, a reaction pathway that avoids the reaction with the 2-amino group is adopted.
- Among these benzimidazole derivatives, as 2-aminobenzimidazole derivatives such as albendazole, fenbendazole, mebendazole, flubendazole, etc., known as anthelmintic agents, are known to exhibit surprising anticancer effects, and are receiving new interest. However, interest is also being given to ways to improve their low water solubility and bioavailability.
- Albendazole and fenbendazole, which are used as anthelmintic agents, are benzimidazole carbamate-based compounds, and are absorbed through the cell wall when absorbed into cells, so that they are absorbed equally by virus-infected cells and normal cells. Therefore, it is difficult to selectively absorb these compounds only in cancer cells or virus-infected cells.
- On the other hand, it has already been reported in various literatures that glucose, which is an energy source of all cells, is absorbed through the GLUT channel of cells, and cells infected with viruses use a greater amount of glucose as an energy source than normal cells (see: BMC Biology (2019) 17:59), (J Virol 89:2358-2366.), (Virology. 2013; 444(1-2):301-9). In addition, it has been reported that in order to use a larger amount of glucose as an energy source than normal cells, virus-infected cells modify the energy metabolism of host cells, activate GLUT channels than normal cells, and rapidly absorb glucose through the GLUT channel to propagate the virus (see: Mol Cancer Ther. 2012 January; 11(1): 14-23).
- In conclusion, it can be seen that cancer cells and virus-infected cells absorb virus-infected cells absorb a relatively large amount of glucose-containing sugar compounds compared to normal cells or non-virus-infected cells.
- In consideration of the above points, a phenomenon in which cancer cells and virus-infected cells absorb excessive amounts of sugar compounds including glucose compared to normal cells or not-infected cells is utilized in the design of new benzimidazole derivatives, and an attempt was made to develop a method that can provide such a new benzimidazole derivative at a simple process and economical cost.
- An object of the present invention is to design a new benzimidazole derivative capable of solving the above-described problems, and to provide a simple and economical preparation method thereof and use thereof as an anticancer or antiviral agent.
- The problem to be solved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned should be clearly understood by those skilled in the art from the following description.
- In order to achieve the above object, the present invention provides a novel benzimidazole-carbohydrate conjugate compound represented by the following Chemical Formula 1:
-
- wherein,
- R1 is a residue of a carbohydrate, and the carbohydrate may be selected from aldotetrose (e.g., erythrose, threose), aldopentose (e.g., ribose, arabinose, xylose, lixose), aldohexose (e.g., allose, altrose, glucose, mannose, glueOS, idose, galactose, tallose), ketotetrose (e.g., erythrolose), ketopentose (e.g., ribulose, xylulose), ketohexose (eg psicose, fructose, sorbose, tagatose), their isomers, oxides (CHO converts to —COOH), deoxy derivatives (—OH converted to —H, e.g., 2-deoxyribose, 2-deoxyglucose), amino sugar (—OH converted to —NH, e.g., N-acetylglucosamine, N-acetylgalactosamine), glycosides, or disaccharides thereof, preferably, may be selected from glucose, fructose, galactose, maltose or xylose;
- R2 and R3 are the same or different and are hydrogen or a substitutable hydrocarbon group, for example, represents an alkyl group having 1 to 10 carbon atoms, an aryl group or a heteroaryl group having 3 to 10 ring atoms, and the alkyl group, the aryl group and the heteroaryl group may be substituted with halogen, cyano, hydroxy, thiol, amino, alkyl, alkyloxy, alkylamino, dialkylamino, aryl, aryloxy, arylamino, diarylamino, aryl or heteroaryl group; and
- X may be selected from the group consisting of —O—, —S—, —SO—, —SO2—, —NH—, —N(R2)-, —CH2—, —CH(R2)—, and —CO—.
- According to one embodiment of the present invention, the benzimidazole-carbohydrate conjugate compound may be a compound represented by the following Chemical Formula 2:
-
- wherein, R1, R2 and X are the same as defined above.
- According to one embodiment of the present invention, in Chemical Formula 1 or 2, the —NH—R1 moiety may have one of the following structures:
- (2-Aminoglucose residue)
- (2-Amino fructose residue)
- (2-Aminogalactose residue)
- (2-Aminomannose residue).
- According to one embodiment of the present invention, in the Chemical Formula 1 or 2, the benzimidazole moiety can have any one of the following structures:
- (Alvedazole residue from which 2-carbamate has been removed)
- (2-Fenbendazole residue from which carbamate has been removed)
- (2-Flubendazole from which carbamate has been removed)
- (2-Mebendazole from which carbamate has been removed).
- According to one embodiment of the present invention, the benzimidazole-carbohydrate conjugate compound may be selected from the following compounds:
- Alfendazole-D-carbohydrate conjugate compound:
- 6-(propylthio)-1H-benzoimidazol-2-aminoglucose,
- 6-(propylthio)-1H-benzoimidazol-2-aminofructose,
- 6-(propylthio)-1H-benzoimidazol-2-aminogalactose, and 6-(propylthio)-1H-benzoimidazol-2-aminomannose;
- Fenbendazole-D-carbohydrate conjugate compound:
- 6-(phenylthio)-1H-benzoimidazol-2-aminoglucose,
- 6-(phenylthio)-1H-benzoimidazol-2-aminofructose,
- 6-(phenylthio)-1H-benzoimidazol-2-aminogalactose, and
- 6-(phenylthio)-1H-benzoimidazol-2-aminomannose;
- Flubendazole-D-carbohydrate conjugate compound:
- 6-(4-fluorobenzoyl)-1H-benzimidazol-2-aminoglucose,
- 6-(4-fluorobenzoyl)-1H-benzimidazol-2-aminofructose,
- 6-(4-fluorobenzoyl)-1H-benzimidazol-2-aminogalactose, and
- 6-(4-fluorobenzoyl)-1H-benzimidazol-2-aminomannose;
- Mebendazole-D-carbohydrate conjugate compound:
- 6-benzoyl-1H-benzimidazol-2-aminoglucose,
- 6-benzoyl-1H-benzimidazol-2-aminofructose,
- 6-benzoyl-1H-benzimidazol-2-aminogalactose, and
- 6-benzoyl-1H-benzimidazol-2-aminomannose.
- In order to achieve the above object, the present invention provides a method for preparing a benzimidazole-carbohydrate conjugate compound represented by the following
Chemical Formula 1, characterized in that a carbohydrate is reacted with a 2-aminobenzimidazole compound represented by the following Chemical Formula 1a. - Specifically, according to the present invention, the benzimidazole-carbohydrate conjugate compound can be prepared by reacting an aldehyde group or a ketone group of a carbohydrate with the 2-amino group of the 2-aminobenzimidazole compound of Chemical Formula 1a to form an imine bond, and cyclizing the carbohydrate moiety:
-
- wherein, in the
Chemical Formulas 1 and 1a, R1, R2, R3 and X are as defined above.
- wherein, in the
- In order to achieve the above object, the present invention provides a pharmaceutical composition containing the benzimidazole-carbohydrate conjugate compound of
Chemical Formula 1. - According to one embodiment of the present invention, the benzimidazole-carbohydrate conjugate compound of
Chemical Formula 1 may inhibit the formation of microtubule and inhibit the absorption of sugar compounds including carbohydrates, preferably glucose. - According to one embodiment of the present invention, the benzimidazole-carbohydrate conjugate compound of
Chemical Formula 1 may exhibit anticancer or antiviral activity. - According to the present invention, a novel benzimidazole-carbohydrate conjugate compound having anticancer or antiviral activity and a method for producing the same are provided.
- It should be understood that the effects of the present invention are not limited to the effects described above, but include all effects that can be inferred from the detailed description of the invention or the constitution of the invention described in the claims.
-
FIG. 1 is a schematic diagram conceptually showing that absorption of glucose is reduced and the growth of virus is inhibited in the GLUT channel. -
FIG. 2 is a diagram showing a growth inhibitory effect of a cancer cell line, which is a result of a toxicity test (24 hours) on a lung cancer cell line. -
FIG. 3 is a diagram showing a growth inhibitory effect of a cancer cell line, which is a result of a toxicity test (72 hours) on a lung cancer cell line. -
FIG. 4 is a diagram showing cell viability in a normal cell line, which is the result of a toxicity test (72 hours) in a normal cell line. -
FIG. 5 is a 1H-NMR spectrum of the albendazole-glucose conjugate compound prepared in Example 1-A. -
FIG. 6 is a 1H-NMR spectrum of the fenbendazole-glucose conjugate compound prepared in Example 1-B. -
FIG. 7 is a 1H-NMR spectrum of the flubendazole-glucose conjugate compound prepared in Example 2-A. -
FIG. 8 is a 1H-NMR spectrum of the mebendazole-glucose conjugate compound prepared in Example 2-B. - Prior to a detailed description of the present invention, it should be understood that the terms and wordings used herein should not be construed to be limited to general or lexical means and the concepts of the terms may be defined to describe the invention made by the inventor(s) of the present invention in the best way, and moreover the terms and wordings should be constructed to have meanings and concepts that agree with the technical spirit of the present invention.
- That is, it should be understood that the terms used herein are used only to described preferred embodiments of the present invention, but are not used to limit the contents of the present invention, and the terms are defined in consideration of various possibilities of the present invention.
- Further, in the specification, a similar expression may include a plural expression unless it is indicated clearly, and a plural expression may include a singular form similarly.
- Throughout the specification, when it is described that an element includes another element, it may mean that the first element may further includes any other element without excluding the other element unless a particularly contradictory description is made.
- In describing the present invention, when it is determined that detailed description of a configuration that may unnecessarily disturb the gist of the present invention, for example, a known technique including a conventional technique, may be omitted.
- First, terms used herein are briefly defined as follows for understanding of the present invention. However, the present invention is not limited by these meanings or definitions of terms.
- The term “anticancer agent” is a substance that inhibits the growth or proliferation of cancer cells, or such drug.
- The term “antiviral” refers to inhibiting the growth of cells infected with a virus, and “antiviral agent” means a substance that inhibits the growth of cells infected with a virus, or such drug.
- The term “carbohydrate” is used as a generic term for organic compounds composed of sugars.
- The term “inhibition of sugar compound absorption” means to inhibit the absorption or entry of sugar compounds into cells.
- The term “tubulin” refers to proteins that make up microtubules present in almost all cells of an organism.
- The term “microtubule” is a tube which consists of a polymer of proteins called tubulin, which constitutes a cytoskeleton and to which intracellular substances move.
- The term “cell division” refers to a phenomenon in which a parent cell of an organism is divided into two cells through nuclear fission and cytoplasmic division.
- The present invention will be described in more detail below.
- (1) Benzimidazole-Carbohydrate Conjugate Compound
- The first object of the present invention is to provide a benzimidazole-carbohydrate conjugate compound represented by the following Chemical Formula 1:
-
- wherein,
- R1 is a residue of a carbohydrate, and the carbohydrate is selected from aldotetrose (e.g., erythrose, threose), aldopentose (e.g., ribose, arabinose, xylose, lixose), aldohexose (e.g., allose, altrose, glucose, mannose, glueOS, idose, galactose, tallose), ketotetrose (e.g., erythrolose), ketopentose (e.g., ribulose, xylulose), ketohexose (eg psicose, fructose, sorbose, tagatose), their isomers, oxides (CHO converts to —COOH), deoxy derivatives (—OH converted to —H, e.g., 2-deoxyribose, 2-deoxyglucose), amino sugar (—OH converted to —NH, e.g., N-acetylglucosamine, N-acetylgalactosamine), glycosides, or disaccharides thereof, preferably, is selected from glucose, fructose, galactose, maltose or xylose;
- R2 and R3 are the same or different and are hydrogen or a substitutable hydrocarbon group, for example, represents an alkyl group having 1 to 10 carbon atoms, an aryl group or a heteroaryl group having 3 to 10 ring atoms, and the alkyl group, the aryl group and the heteroaryl group may be substituted with halogen, cyano, hydroxy, thiol, amino, alkyl, alkyloxy, alkylamino, dialkylamino, aryl, aryloxy, arylamino, diarylamino, aryl or heteroaryl group; and
- X may be selected from the group consisting of —O—, —S—, —SO—, —SO2—, —NH—, —N(R2)-, —CH2—, —CH(R2)—, and —CO—.
- The compound of the
Chemical Formula 1 may be understood as a form in which a carbohydrate residue is bound to a 2-amino group of the 2-aminobenzimidazole structure or a form in which an aminated carbohydrate is bound to the 2-position of the benzimidazole structure. - According to one embodiment of the present invention, the benzimidazole-carbohydrate conjugate compound can be a compound represented by the following
Chemical Formula 2. -
- wherein, R1, R2 and X are the same as defined above.
- According to one embodiment of the present invention, in Chemical Formula 1 or 2, the —NH—R1 moiety may have one of the following structures:
- (2-Aminoglucose residue)
- (2-Amino fructose residue)
- (2-Aminogalactose residue)
- (2-Aminomannose residue)
- According to one embodiment of the present invention, in the Chemical Formula 1 or 2, the benzimidazole moiety can have any one of the following structures:
- (Alvedazole residue from which 2-carbamate has been removed)
- (2-Fenbendazole residue from which carbamate has been removed)
- (2-Flubendazole from which carbamate has been removed)
- (2-Mebendazole from which carbamate has been removed)
- According to one embodiment of the present invention, the benzimidazole-carbohydrate conjugate compound may be selected from the following compounds:
- Alfendazole-D-carbohydrate conjugate compound:
- 6-(propylthio)-1H-benzoimidazol-2-aminoglucose,
- 6-(propylthio)-1H-benzoimidazol-2-aminofructose,
- 6-(propylthio)-1H-benzoimidazol-2-aminogalactose, and 6-(propylthio)-1H-benzoimidazol-2-aminomannose;
- Fenbendazole-D-carbohydrate conjugate compound:
- 6-(phenylthio)-1H-benzoimidazol-2-aminoglucose,
- 6-(phenylthio)-1H-benzoimidazol-2-aminofructose,
- 6-(phenylthio)-1H-benzoimidazol-2-aminogalactose, and
- 6-(phenylthio)-1H-benzoimidazol-2-aminomannose;
- Flubendazole-D-carbohydrate conjugate compound:
- 6-(4-fluorobenzoyl)-1H-benzimidazol-2-aminoglucose,
- 6-(4-fluorobenzoyl)-1H-benzimidazol-2-aminofructose,
- 6-(4-fluorobenzoyl)-1H-benzimidazol-2-aminogalactose, and
- 6-(4-fluorobenzoyl)-1H-benzimidazol-2-aminomannose;
- Mebendazole-D-carbohydrate conjugate compound:
- 6-benzoyl-1H-benzimidazol-2-aminoglucose,
- 6-benzoyl-1H-benzimidazol-2-aminofructose,
- 6-benzoyl-1H-benzimidazol-2-aminogalactose, and
- 6-benzoyl-1H-benzimidazol-2-aminomannose.
- In the benzimidazole-carbohydrate conjugate compound according to the present invention, the carbohydrate moiety has both a chain structure and a cyclic structure, and the chain structure is thermodynamically more stable in the pentose and hexose, but the chain structure and the cyclic structure are in equilibrium in the solution, Thus, even if only one of the two has a medicinal effect, it does not have a significant effect on the overall pharmacological effect.
- (2) Method for Preparing Benzimidazole-Carbohydrate Conjugate Compound
- To solve the above objects, the present invention provides a method for preparing a benzimidazole-carbohydrate conjugate compound represented by the following
Chemical Formula 1, characterized in that a carbohydrate is reacted with a 2-aminobenzimidazole compound of the following Chemical Formula 1a to form an imine bond. Specifically, according to the present invention, the benzimidazole carbohydrate conjugate compound represented byChemical Formula 1 can be prepared by reacting an aldehyde group or a ketone group of a carbohydrate with ae 2-amino group of the 2-aminobenzimidazole compound of Formula 1a to form an imine bond, and cyclizing the carbohydrate moiety. - in the
Chemical Formulas 1 and 1a, R1, R2, R3 and X are the same as defined above. - According to one embodiment of the present invention, in the 2-aminobenzimidazole compound of Formula 1a, a substituent capable of performing an imine reaction may be previously protected or blocked.
- The benzimidazole-carbohydrate conjugate compound according to the present invention can be prepared by various methods, and an example of the preparation method is provided below.
- As an example of preparing the benzimidazole-carbohydrate conjugate compound according to the present invention, the following
Reaction Scheme 1 may be presented. -
Reaction Scheme 1 shows a reaction in which a D-glucose unit is bound to the 2-amino group of 6-alkylthio-2-aminobenzimidazole, which is a precursor of albendazole or fenbendazole. - In
Reaction Scheme 1, an 2-amino group of aminobenzimidazole can be reacted with an aldehyde group of D-glucose (open chain form) to form an imine bond, and thereby, a benzimidazole-carbohydrate conjugate compound, that is, benzimidazole-D-glucose (open chain form) conjugate compound is prepared. - The benzimidazole-D-glucose (open chain form) conjugate compound may be converted into thermodynamically stable cyclic benzimidazole-D-glucose (cyclic form).
- As another example of preparing the benzimidazole-carbohydrate conjugate compound according to the present invention, the following
Reaction Scheme 2 can be presented. -
Reaction Scheme 2 shows the reaction of binding the D-glucose unit to the 2-amino group of 6-alkylcarbonyl-2-aminobenzimidazole, which is a precursor of flubendazole or mebendazole. - The benzimidazole-carbohydrate conjugate compound obtained as a result of
Reaction Schemes - (3) Pharmacological Effects and Uses of Benzimidazole-Carbohydrate Conjugate Compounds
- A third object of the present invention is to provide a pharmaceutical composition or a pharmacological composition containing the benzimidazole-carbohydrate conjugate compound of
Chemical Formula 1. - According to one embodiment of the present invention, the benzimidazole-carbohydrate conjugate compound of
Chemical Formula 1 can exhibit a pharmacological effect of inhibiting the formation of microtubule and the absorption of carbohydrates, preferably sugar compounds including glucose, and thereby, a pharmacological composition useful for the treatment of disorders that can take advantage of intake or metabolic disorders of carbohydrates, including glucose, can be provided. - According to an embodiment of the present invention, the benzimidazole-carbohydrate conjugate compound of
Formula 1 exhibits anticancer or antiviral activity, so that a pharmaceutical composition having anticancer or antiviral activity may be provided. - One of the features of the present invention is that when the fenbendazole-glucose compound (FB-G), which is one of the benzimidazole-carbohydrate conjugate compounds, is absorbed into cells in the form of glucose bound to fenbendazole, it has been designed so as to be absorbed through the GLUT channel rather than the cell wall by glucose bound to this compound. It is known that the GLUT channel is more activated in cancer cells or virus-infected cells than in normal cells. In particular, it has been reported that cancer cells form 1000 times more GLUT channels than normal cells. The benzimidazole-carbohydrate conjugate compound according to the present invention is expected to be more intensively absorbed in cancer cells and virus-infected cells in which GLUT channels are activated than in normal cells (see: L. Quan et al. I Journal of Molecular Structure 1203 (2020) 127361).
- According to an embodiment of the present invention, there is provided a pharmacological composition in which the benzimidazole-carbohydrate conjugate compound of
Chemical Formula 1 is absorbed through a GLUT channel rather than a cell wall. - The fact that the benzimidazole-carbohydrate conjugate compound of
Chemical Formula 1 according to the present invention exhibits antiviral activity can be explained as follows. - A virus is a small particle (average 0.1 um or less) that are smaller a bacteria and cannot be filtered through a bacterial filter (0.22 um), and contains only nucleic acids (DNA or RNA) and a small number of proteins as substances necessary for survival, so it is an organism that lives depending on the host, and if it is infected in the human body, it causes viral diseases.
- Viruses differ in most properties from bacteria, and common antibiotics do not inhibit the growth of virus. As a therapeutic agent for diseases caused by viruses, drugs that weaken or eliminate the action of viruses that have invaded the body are called antiviral therapeutic agents. Because viral infections are difficult to treat with conventional antibiotics, they have no choice but to treat them with antiviral therapeutic agent.
- Antiviral preparations currently being developed and used are drugs that inhibit the growth process of the virus, that is, inhibit the growth rate of the intracellular virus infected with virus, extremely inhibit the number of cells infected with the virus from being increased, so that the body's immune system attacks virus-infected cells and inhibites the virus's growth process below levels that can be removed.
- Antiviral drugs that inhibit the growth of virus are drugs that inhibit the growth of a virus is a drug that inhibites and treats the growth of a virus by interfering with a specific step in the process of the growth of the virus in the cell.
- Antiviral agents are classified into influenza therapeutic agents, herpes therapeutic agents, hepatitis B therapeutic agents, hepatitis C therapeutic agents, AIDS therapeutic agents, etc., depending on the disease group to be treated, and may be used for various diseases depending on the characteristics of the drug.
- Typical antiviral drugs used as influenza therapeutic agents include Tamiflu®, Relenzarotadisk® and Peramivir®, which are used for the treatment of influenza A and influenza B virus infections.
- As a herpes therapeutic agent, typical antiviral agents used for the treatment of herpes simplex virus (HSV) and varicella zoster virus (VZV) infection are Zovirax®, Valtrex®, Famciclovir®, Ocufridine®, and the like.
- A therapeutic agent for hepatitis C is a drug that inhibits the growth of hepatitis C virus and delays the progression of the diseases. The combination therapy of interferon injection and ribavirin, which enhances the immune system, has been used for a long time, but relatively recently, direct acting antivirals (DAA) have been developed, and can be treated with just edible drugs, and typical examples are Viramid®, Exviera®, Sovaldi®, Daclatarvir®, and Harvoni®, and the like.
- As AIDS therapeutic agents, a drug that inhibites the growth of human immunodeficiency virus (HIV) and delays the progression of the disease is to prevent the expression of resistance by using cocktail therapy in which three or more drugs are taken at the same time, and typical examples are Combivir®, Kivexa®, Trubada®, and Intelence®, and the like.
- As other antiviral agents, there are drugs that inhibit the growth of viruses by enhancing or regulating human immune responses, which are substances produced and secreted by immune cells during infection, and have antiviral effect and immunomodulatory ability. Typical examples are Loferon-A®, Intron-A®, Pegasys®, and Aldara® are typical (see: Korea Pharmaceutical Information Center).
- However, until now, the types and numbers of antiviral preparations that successfully treat viral infections are so poor that most viral infections are expected to be self-healing by the patient's immune function (Rider et al., 2011).
- Development of drugs that inhibit the growth rate of virus-infected intracellular virus, ultimately inhibit virus-infected cells from being increased, so that the internal immune system can attack and eliminate virus-infected cells and inhibit the viral growth process below a level that can be removed, is urgently needed.
- One of the advantages of the present invention is that the novel benzimidazole-carbohydrate conjugate compound according to the present invention is mainly absorbed only in cancer cells and virus-infected cells than in normal cells, and then binds to tubulin that forms microtubules, which is a known characteristic of conventional benzimidazole compound derivatives, and interferes with the formation of microtubule, inhibits cell division, whereby it is possible to effectively induce the death of cancer cells and virus-infected cells by blocking the absorption of carbohydrates containing glucose, which is a cellular energy source.
- Therefore, since the novel benzimidazole-carbohydrate conjugate compound according to the present invention is absorbed intensively by cancer cells and virus-infected cells, not only it is designed to minimize toxicity to normal cells, but also it is expected to be usefully used as an anticancer and antiviral compound for the treatment of cancer and virus-infections.
- Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are for more specific explanation of the present invention, and the scope of the present invention is not limited by the examples. The following examples can be appropriately modified or changed by those skilled in the art within the scope of the present invention.
-
- An albendazole-glucose conjugate compound was prepared according to the above reaction scheme, and the reaction procedure and conditions were referred to the methods described in documents (Gokhale, Kearney, and Kirsch, AAPS PharmSciTech, Vol. 10, No. 2, June 2009). 1.2 mM aminoalbendazole (CAS #80983-36-4) (commercially available: Albendazole amine) and 0.5 M glucose were added to a hydrochloric acid solution (pH 3.45) to prepare a reaction mixture, and reacted at 40±1° C. in a Teflon-coated rubber-stopped glass vial, and diluted with acetate buffer (0.5 M, pH 5.8) to terminate the reaction.
- The solvent was removed, and purified by column chromatography using dichloromethane and 10% methanol to obtain an albendazole-glucose conjugate compound in a yield of 62%.
- The product was analyzed by 1H-NMR spectrum to confirm the formation of an albendazole-glucose conjugate compound (see
FIG. 5 ). -
- The procedure was performed in the same manner as in Example 1-A, except that aminophenbendazole (CAS #1448346-29-9) (hydrochloride form) was used instead of amino albendazole, thereby obtaining a fenbendazole-glucose conjugate compound as a benzimidazole-carbohydrate conjugate compound in a yield of 66%.
- The product was analyzed by 1H-NMR spectrum to confirm generation of a fenbendazole-glucose conjugate compound (see
FIG. 6 ). -
- A flubendazole-glucose conjugate compound was prepared according to the reaction scheme, and the reaction procedure and conditions were referred to the methods described in documents (Gokhale, Kearney, and Kirsch, AAPS PharmSciTech, Vol. 10, No. 2, June 2009). 1.2 mM aminoflubendazole (CAS #82050-13-3) (commercial name: 2-Aminoflubendazole) and 0.5 M glucose were added to a hydrochloric acid solution (pH 3.45) to prepare a reaction mixture, reacted at 40±1° C. in a Teflon-coated rubber-stopped glass vial, and diluted with acetate buffer (0.5 M, pH 5.8) to terminate the reaction.
- The solvent was removed, and purified by column chromatography using dichloromethane and 10% methanol to obtain a flubendazole-glucose conjugate compound in a yield of 68%.
- The product was analyzed by 1H-NMR spectrum to confirm the formation of a flubendazole-glucose conjugate compound (see
FIG. 7 ). -
- The procedure was performed in the same manner as in Example 2-A, except that aminomebendazole (CAS #52329-60-9) was used instead of aminoflubendazole, thereby obtaining a mebendazole-glucose conjugate compound in a yield of 66%.
- The product was analyzed by 1H-NMR spectrum to confirm the formation of a mebendazole-glucose conjugate compound (see
FIG. 8 ). - Human lung cancer cell line A549, cervical cancer cell line Hela, and colorectal cancer cell line HT-29 were furnished from Korea Cell Line Bank (KCLB, Seoul, Korea) and cultured in culture medium.
- In a humidified cell culture incubator containing 5% CO2 at 37° C. using DMEM, 10% culture flask, fetal bovine serum (FBS), 0.1 mM MEM non-essential amino acids (NEAA), 2 mM L-glutamine, and 1% penicillin-streptomycin were treated with trypsin every 2-3 days according to the guidelines provided by KCLB, and the cells were sub-cultured. The culture was cultured until it reached 80-90% confluence, and the cells were continuously transferred to a culture flask for a cancer cell line growth inhibition experiment.
- Cancer cell lines to be tested (human lung cancer cell line A549, cervical cancer cell line Hela, and colorectal cancer cell line HT-29) were seeded in about 10000 cells per well in a 96-well plate. After 24 hours, the three compounds shown in Table 1 below were added to each well at 7 concentrations, and incubated for 72 hours.
- In Table 1, aminophenbendazole and doxorubicin were commercially available compounds, and the fenbendazole-glucose conjugate used was the one prepared in Example 1-B.
- After incubation, the medium was discarded and the cell viability was measured in each well using a WST-8 cell viability assay kit (Quanti-Max™, BIOMAX) according to the procedure instructed by the manufacturer.
- The analysis utilized the principle that the dehydrogenase in living cells decomposes tetrazolium salts to produce formazan, through which living cells were quantitatively evaluated.
- The reduced formazan salt is soluble in the cell culture medium and the amount of formazan is directly proportional to the number of viable cells (see: Slater, T. et al. (1963) Biochem. Biophys. Acta 77:383; van de Loosdrecht, A A, et al. J. Immunol. Methods 174: 311-320, 1994. Alley, M C, et al.; and Cancer Res. 48: 589-601, 1988.)
- The results of the cancer cell line growth inhibition test performed in this test example are shown in
FIGS. 2 and 3 .FIG. 2 is the results of a toxicity test (24 hr) in a lung cancer cell line, andFIG. 3 is the results of a toxicity test (72 hr) in a lung cancer cell line. - The normal lung cell line MRC-5 and the normal colon CCD-18Co cell line were furnished from Korea Cell Line Bank (KCLB, Seoul, Korea) and cultured in culture medium.
- In a humidified cell culture incubator containing 5% CO2 at 37° C. using DMEM, 10% culture flask, fetal bovine serum (FBS), 0.1 mM MEM non-essential amino acids (NEAA), 2 mM L-glutamine, and 1% penicillin-streptomycin were treated with trypsin every 2-3 days according to the guidelines provided by KCLB, and the cells were sub-cultured. The culture was cultured until it reached 80-90% confluence, and the cells were continuously transferred to a culture flask for a cancer cell line growth inhibition experiment.
- Normal cell lines (MRC-5 and CCD-18Co) were seeded in about 10000 cells per well in a 96-well plate. After 24 hours, the three compounds shown in Table 1 below were added to each well at 7 concentrations, and incubated for 72 hours.
- The cell viability and analysis in the normal cell line were performed in the same manner as in Test Example 1, and the results of the toxicity test (72 hours) in the normal cell line are shown in
FIG. 4 . Table 3 below shows that the test results of aminofenbendazole and fenbendazole-glucose conjugate compound were evaluated in comparison with doxorubicin. -
TABLE 3 Cancer cell Normal cell line growth line growth inhibition test inhibition test Aminophenbendazole C A A A Phenbendazole- A A A A A A glucose conjugate - As can be seen from Table 3, it was confirmed that aminophenbendazole of the prior art has significantly better normal cell line toxicity test results than doxorubicin (AAA), but cancer cell line growth inhibition test result was normal (C), whereas the phenbendazole-glucose conjugate according to the present invention is significantly superior to doxorubicin in both the cancer cell line growth inhibition test and the normal cell line toxicity test (AAA).
- Although specific examples of the novel benzimidazole derivative according to the present invention, a method for preparing the same, and its use as an anticancer agent or an antiviral agent have been described so far, it would be apparent that various modifications can be made to the invention within the scope of the present invention.
- Therefore, the scope of the present invention should not be defined only by the above-described embodiment, but must be defined not only by the claims described later but also by something equivalent to the scope of claims.
- That is, it must be understood that the above-described embodiments are exemplary in all respects and is not limiting, and the scope of the present invention is specified in the claims described below rather than the detailed description. The meaning and scope of the claims and all modified or changed forms derived from the equivalent concept shall be construed as being included in the scope of the invention.
- The present invention is available in the pharmaceutical, medical and health industries.
Claims (3)
1. A method for preparing a benzimidazole-carbohydrate conjugate compound represented by the following Chemical Formula 1, comprising the steps of: reacting a carbohydrate with a 2-aminobenzimidazole compound of Chemical Formula 1a to form an imine bond:
wherein,
in the Chemical Formulas 1 and 1a,
R1 is a residue of a carbohydrate, and the carbohydrate is selected from aldotetrose (e.g., erythrose, threose), aldopentose (e.g., ribose, arabinose, xylose, lixose), aldohexose (e.g., allose, altrose, glucose, mannose, glueOS, idose, galactose, tallose), ketotetrose (e.g., erythrolose), ketopentose (e.g., ribulose, xylulose), ketohexose (eg psicose, fructose, sorbose, tagatose), their isomers, oxides (CHO converts to —COOH), deoxy derivatives (—OH converted to —H, e.g., 2-deoxyribose, 2-deoxyglucose), amino sugar (—OH converted to —NH, e.g., N-acetylglucosamine, N-acetylgalactosamine), glycosides, or disaccharides thereof, preferably, is selected from glucose, fructose, galactose, maltose or xylose;
R2 and R3 are the same or different and are hydrogen or a substitutable hydrocarbon group, for example, represents an alkyl group having 1 to 10 carbon atoms, an aryl group or a heteroaryl group having 3 to 10 ring atoms, and the alkyl group, the aryl group and the heteroaryl group may be substituted with halogen, cyano, hydroxy, thiol, amino, alkyl, alkyloxy, alkylamino, dialkylamino, aryl, aryloxy, arylamino, diarylamino, aryl or heteroaryl group; and
X can be selected from the group consisting of —O—, —S—, —SO—, —SO2—, —NH—, —N(R2)-, —CH2—, —CH(R2)—, and —CO—.
2. The method for preparing a benzimidazole-carbohydrate conjugate compound according to claim 1 , wherein in the 2-aminobenzimidazole compound of Chemical Formula 1a, a substituent capable of performing an imine reaction is previously protected or blocked.
3. The method for preparing a benzimidazole-carbohydrate conjugate compound according to claim 1 , wherein in the 2-aminobenzimidazole compound of Chemical Formula 1a, a substituent capable of performing an imine reaction is previously protected or blocked.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/370,241 US20240018178A1 (en) | 2020-06-23 | 2023-09-19 | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0076802 | 2020-06-23 | ||
KR1020200076802A KR102449266B1 (en) | 2020-06-23 | 2020-06-23 | Novel benzimidazole-carbohydrate conjugate compounds with anti-cancer activity and antiviral activity and their manufacturing method |
PCT/KR2020/013371 WO2021261663A1 (en) | 2020-06-23 | 2020-09-29 | Novel benzimidazole derivative, preparation method therefor, and use thereof as anticancer or antiviral agent |
US17/051,154 US20210395289A1 (en) | 2020-06-23 | 2020-09-29 | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same |
US18/370,241 US20240018178A1 (en) | 2020-06-23 | 2023-09-19 | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/013371 Division WO2021261663A1 (en) | 2020-06-23 | 2020-09-29 | Novel benzimidazole derivative, preparation method therefor, and use thereof as anticancer or antiviral agent |
US17/051,154 Division US20210395289A1 (en) | 2020-06-23 | 2020-09-29 | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240018178A1 true US20240018178A1 (en) | 2024-01-18 |
Family
ID=79023128
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/051,154 Pending US20210395289A1 (en) | 2020-06-23 | 2020-09-29 | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same |
US18/370,241 Pending US20240018178A1 (en) | 2020-06-23 | 2023-09-19 | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/051,154 Pending US20210395289A1 (en) | 2020-06-23 | 2020-09-29 | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same |
Country Status (4)
Country | Link |
---|---|
US (2) | US20210395289A1 (en) |
EP (1) | EP4169930A1 (en) |
JP (1) | JP7376108B2 (en) |
CN (1) | CN114096549A (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5248672A (en) | 1990-11-01 | 1993-09-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
GB9413724D0 (en) | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
GB9600143D0 (en) | 1996-01-05 | 1996-03-06 | Wellcome Found | Therapeutic compounds |
CN1265665A (en) * | 1997-06-10 | 2000-09-06 | 葛兰素集团有限公司 | Benzimidazole derivatives |
CA2297076A1 (en) | 1997-07-30 | 1999-02-11 | The Regents Of The University Of Michigan | Lyxofuranosyl benzimidazoles as antiviral agents |
CA2972635A1 (en) * | 2015-01-06 | 2016-07-14 | Immunovaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
CN106892948B (en) * | 2015-12-17 | 2022-07-26 | 宜昌东阳光长江药业股份有限公司 | Glucopyranosyl derivative and application thereof in medicine |
-
2020
- 2020-09-29 EP EP20793233.6A patent/EP4169930A1/en active Pending
- 2020-09-29 JP JP2020560771A patent/JP7376108B2/en active Active
- 2020-09-29 US US17/051,154 patent/US20210395289A1/en active Pending
- 2020-09-29 CN CN202080002572.7A patent/CN114096549A/en active Pending
-
2023
- 2023-09-19 US US18/370,241 patent/US20240018178A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4169930A1 (en) | 2023-04-26 |
US20210395289A1 (en) | 2021-12-23 |
JP7376108B2 (en) | 2023-11-08 |
CN114096549A (en) | 2022-02-25 |
JP2022541356A (en) | 2022-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1319931C (en) | Antiviral antitumor antimetastatic immune system enhancing nucleosides and nucleotides | |
CN114437159B (en) | Cyclic carbonate nucleoside compound and application thereof | |
JPH10507772A (en) | L-ribofuranosyl nucleoside | |
WO2007135380A2 (en) | Antiparasitic compounds and compositions | |
US20210038628A1 (en) | Nanoparticle compositions | |
US20130303747A1 (en) | Pyrimidine nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments | |
US5180714A (en) | Adenosine compounds for the treatment of diseases caused by parasitic protozoa | |
US20240018178A1 (en) | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same | |
AU732120B2 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
US20210300959A1 (en) | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same | |
KR102449266B1 (en) | Novel benzimidazole-carbohydrate conjugate compounds with anti-cancer activity and antiviral activity and their manufacturing method | |
US5593999A (en) | Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT) | |
KR102583547B1 (en) | Novel benzimidazole derivatives, preparation thereof and use thereof as anti-cancer agent comprising the same | |
KR102342313B1 (en) | Micelle comprising benzimidazole-carbohydrate conjugate compound, preparation thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same | |
US8173610B2 (en) | Derivatives of epirubicin, their medicinal application and pharmaceuticaly acceptable forms of drugs | |
US10590158B2 (en) | Total synthesis of shishijimicin A and analogs thereof | |
US20180280418A1 (en) | Compositions and methods for treatment of inflammatory disorders | |
US20170232031A1 (en) | Inhibitors of Zika Virus | |
US7253177B2 (en) | Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives | |
RU2629670C2 (en) | 2-amino-5,6-difluor-1-(beta-d-ribofuranosyl)-benzimidazole, method for production and antiviral activity in terms of herpes simplex virus type i | |
WO2024030429A1 (en) | Base-modified ribonucleosides as prodrugs against viral and bacterial infections | |
US20210230178A1 (en) | Trioxacarcin analogs and dimers as potent anticancer agents | |
CN117343072A (en) | 1-substituted cinnamoyl-2-oxo lycorine compound and preparation method and application thereof | |
CN1460109A (en) | Improved specificity in treatment of diseases | |
WO2022043531A1 (en) | 7'-substituted 2'-o-4'-c-ethylene-bridged nucleic acid (ena) monomers and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOMETRIX TECHNOLOGY INC, KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, JUNGHUN;SONG, KEUMSOO;KIM, TAISUN;REEL/FRAME:064957/0399 Effective date: 20201027 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |